PDS Biotechnology Dividends and Buybacks
Dividend criteria checks 0/6
PDS Biotechnology does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-47.6%
Buyback Yield
| Total Shareholder Yield | -47.6% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk
Jan 13PDS Biotech jumps 13% as FDA clears further development of lead asset
Oct 03PDS Biotechnology files for $150 mixed shelf offering
Aug 24PDS Biotech spikes as panel backs continuation of cancer trial for lead asset
Aug 04PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business
Jul 08
PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
May 27PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
Feb 22PDS Biotech: Looking Attractive Despite 52-Week High Price
Sep 19PDS Biotech under pressure after pricing equity offering at $8.50
Jun 15Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if PDSB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PDSB's dividend payments have been increasing.
Dividend Yield vs Market
| PDS Biotechnology Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (PDSB) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (PDSB) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate PDSB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PDSB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate PDSB's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PDSB has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 00:19 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PDS Biotechnology Corporation is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |